This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients

Sponsored by Pherecydes Pharma

About this trial

Last updated 10 years ago

Study ID

PHAGOBURN

Status

Unknown status

Type

Interventional

Phase

Phase 1/Phase 2

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 10 years ago

What is this trial about?

The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage treatment of E. coli or P. aeruginosa wound infections in burned patients.

What are the participation requirements?

Yes

Inclusion Criteria

- Man or woman

- Adult Informed consent obtained from patient or next of kin

- In-hospital patient treated for burn wounds in a burn unit

- Burn wound (grafted or not) or graft harvesting area, presenting local signs of infection defined by SFETB criteria:

- A local or loco-regional inflammatory reaction;
- And/or an adverse and unexpected local evolution;
- And/or regarding burn wounds: presence of pus, fast spontaneous debridement and separation, occurrence of blackish spots (necrosis or haemorrhage), unexplained conversion from a superficial lesion to a deep one (> 48th hour);
- And/or regarding graft donor sites: presence of pus, unexplained delay in epidermisation, bedsore;
- And/or regarding graft recipient sites: presence of pus, lysis of grafts, necrosis of fat located under the graft.

- Burn wounds with a microbiologically documented infection, as defined by positive surface swab, due to Escherichia coli or Pseudomonas aeruginosa whatever their resistance profile

- Treated by povidone-iodine

No

Exclusion Criteria

- Pregnant or breastfeeding woman

- Intercurrent condition requiring a treatment which may interfere with analysis results: such as high dose of chronic corticotherapy, immunosuppressive medication, oncologic chemotherapy

- Patient included in an interventional research protocol with therapeutic intervention still ongoing upon inclusion time or having participated into anti-infective drug trials during the previous month.

- Patient considered as part of a vulnerable population

- Patient for whom treatment limitation or withdrawal during study period is considered

- Allergy to Silver Sulfadiazine

Locations

Location

Status

Recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting